Finally, we explored the potential prognostic value of common candidate genes from the most significantly enriched pathways and found an association with worse relapse free survival and high PDHB (upregulated in PRA transgenics, Fig. 4) or low LAMB3 (downregulated in PRA transgenics, Fig. 5) for luminal breast cancer subtypes. The gene discussed is PDHB; the disease is breast carcinoma.